Pharma marketers have more data, channels, and technology at their disposal than ever. But engaging audiences across every stage of their health journey, with relevant and timely messaging remains complex. At Fierce Pharma Week 2026, we discussed what challenges this tension creates for pharma marketers—and what that means for the next phase of pharma marketing.
Whether you were on the ground shaping discussions or missed the conference, we’ve got you covered with the three biggest takeaways from Fierce Pharma Week 2026.
Today’s pharma marketers rely heavily on ID- and claims-based data to reach and engage audiences. This information becomes available to pharma marketers only after diagnosis, which means marketers can only strategically engage audiences months, sometimes years, after their symptoms first appear.
By relying on traditional targeting methods, the pharma industry misses large portions of its patient audience and creates blind spots in the health journey.
Pharma marketers are shifting toward solutions that enable them to reach audiences earlier in their journey, reducing misdiagnosis and helping patients access life-changing education and treatment sooner.
Patients and caregivers move seamlessly across channels and devices. But today’s tech is siloed and fragmented, preventing marketers from engaging audiences more effectively, managing brand-to-consumer interactions, and measuring campaigns just as seamlessly.
That fragmentation, combined with state-by-state privacy and compliance laws, makes delivering connected experiences even more complex and directly impacts campaign scale, reach, and campaign outcomes—and the overall health journey.
Marketers need solutions that unify the advertising ecosystem across audiences, data, and media to provide a unified view of the entire patient journey, improving media planning, buying, and measurement.
While AI adoption has accelerated within pharma marketing, many are finding that adding AI to fragmented workflows is not driving efficiency. In some cases, marketers must navigate multiple platforms and AI tools to activate data, optimize campaigns, and understand performance, worsening the “swivel chair” problem they hoped AI would solve. The industry has moved from demanding more AI-enabled technologies to demanding more interoperability.
Moreover, advertisers worry about the implications of leveraging AI without sufficient transparency or guardrails. Throughout the conference, marketing leaders touted the importance of seeking partners that let them retain control and strengthen decision-making with guardrails and transparency.
These three takeaways signal a larger, persistent issue in pharma marketing. But access to more data and tech doesn’t necessarily mean better campaign outcomes.
To succeed, pharma marketers must move away from siloed systems and adopt unified approaches that bring audiences, data, and media together. With a unified foundation, marketers can layer on AI to operate across their marketing tech stack rather than in siloes
That’s the challenge Cadent solves. The Cadent Platform unifies media planning, buying, and measurement all in one place helping marketers drive better campaign outcomes than siloed legacy technology can deliver. What’s more, Cadent Total Health Audiences combines the certainty of ID-based audiences with the power of predictive intelligence to capture the entire patient audiences across every stage in the patient journey, every state, and all screens.
Download our one sheet to learn how you can uncover untapped audiences and anticipate outcomes all screens, all while keeping privacy at the center of your campaigns.